HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Petra Heffeter Selected Research

Thiosemicarbazones

11/2021Liposomal formulations of anticancer copper(II) thiosemicarbazone complexes.
11/2020Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux.
10/2019Anticancer Thiosemicarbazones: Chemical Properties, Interaction with Iron Metabolism, and Resistance Development.
1/2019Synthesis and biological evaluation of biotin-conjugated anticancer thiosemicarbazones and their iron(III) and copper(II) complexes.
10/2018The thiosemicarbazone Me2NNMe2 induces paraptosis by disrupting the ER thiol redox homeostasis based on protein disulfide isomerase inhibition.
3/2018Comparison of metabolic pathways of different α-N-heterocyclic thiosemicarbazones.
1/2016Differences in protein binding and excretion of Triapine and its Fe(III) complex.
6/2012Impact of terminal dimethylation on the resistance profile of α-N-heterocyclic thiosemicarbazones.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Petra Heffeter Research Topics

Disease

77Neoplasms (Cancer)
12/2021 - 03/2007
12Carcinoma (Carcinomatosis)
02/2021 - 02/2006
8Lung Neoplasms (Lung Cancer)
02/2021 - 06/2013
6Colorectal Neoplasms (Colorectal Cancer)
10/2021 - 01/2016
5Colonic Neoplasms (Colon Cancer)
01/2022 - 03/2014
5Hypoxia (Hypoxemia)
12/2020 - 11/2014
5Melanoma (Melanoma, Malignant)
10/2017 - 10/2009
3Hematologic Diseases (Blood Diseases)
01/2020 - 01/2016
3Mesothelioma
10/2014 - 06/2013
2Neoplasm Metastasis (Metastasis)
02/2021 - 04/2016
2Sarcoma (Soft Tissue Sarcoma)
12/2020 - 10/2016
2Osteosarcoma (Osteogenic Sarcoma)
11/2018 - 12/2017
2Leukemia L1210
01/2017 - 01/2014
2Malignant Mesothelioma
10/2016 - 10/2014
2Acute Promyelocytic Leukemia
05/2016 - 06/2013
2Hepatocellular Carcinoma (Hepatoma)
12/2015 - 10/2013
2Breast Neoplasms (Breast Cancer)
07/2009 - 12/2007
1Hypersensitivity (Allergy)
01/2022
1Pancreatic Neoplasms (Pancreatic Cancer)
01/2022
1Triple Negative Breast Neoplasms
01/2021
1Intestinal Diseases (Diseases, Intestinal)
09/2020
1Malaria
10/2019
1Virus Diseases (Viral Diseases)
10/2019
1Iron Overload
10/2019
1Tuberculosis (Tuberculoses)
10/2019

Drug/Important Bio-Agent (IBA)

23Pharmaceutical PreparationsIBA
10/2021 - 03/2007
12ProdrugsIBA
10/2021 - 11/2014
113-aminopyridine-2-carboxaldehyde thiosemicarbazone (triapine)IBA
11/2021 - 06/2012
9Proteins (Proteins, Gene)FDA Link
12/2021 - 12/2007
9Biological ProductsIBA
03/2020 - 04/2012
8ThiosemicarbazonesIBA
11/2021 - 06/2012
8MetalsIBA
01/2021 - 02/2008
8Cisplatin (Platino)FDA LinkGeneric
12/2017 - 02/2006
7Oxaliplatin (Eloxatin)FDA LinkGeneric
10/2021 - 02/2008
7PlatinumIBA
10/2021 - 02/2008
7LigandsIBA
01/2021 - 01/2009
6Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA
12/2018 - 10/2011
6Phosphotransferases (Kinase)IBA
12/2015 - 09/2009
5RutheniumIBA
01/2022 - 06/2010
5Tyrosine Kinase InhibitorsIBA
12/2020 - 11/2016
4Messenger RNA (mRNA)IBA
02/2021 - 04/2012
4indazolium trans- (tetrachlorobis(1H- indazole)ruthenate (III))IBA
01/2014 - 01/2009
3IndazolesIBA
01/2022 - 01/2009
3AlbuminsIBA
10/2021 - 03/2017
3Small Interfering RNA (siRNA)IBA
02/2021 - 04/2012
3PD 173074IBA
12/2018 - 06/2017
3nintedanibIBA
11/2018 - 08/2016
3GalliumIBA
12/2017 - 10/2009
3Antineoplastic Agents (Antineoplastics)IBA
10/2016 - 02/2008
2SodiumIBA
01/2022 - 01/2017
2Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
02/2021 - 11/2014
2maleimideIBA
01/2021 - 03/2017
2IronIBA
12/2020 - 10/2019
2Glutathione (Reduced Glutathione)IBA
11/2020 - 02/2013
2CopperIBA
11/2020 - 01/2020
2ponatinibIBA
01/2020 - 11/2018
2CrizotinibIBA
01/2020 - 05/2016
2satraplatin (JM 216)IBA
12/2019 - 08/2015
2sigma-2 receptorIBA
01/2018 - 01/2017
2OsmiumIBA
01/2018 - 02/2013
2Peptides (Polypeptides)IBA
06/2017 - 01/2017
2Type 3 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 3)IBA
06/2017 - 12/2015
2ErbB Receptors (EGF Receptor)IBA
06/2017 - 06/2013
2IntegrinsIBA
01/2017 - 10/2014
2Erlotinib Hydrochloride (CP 358,774)FDA Link
11/2016 - 06/2013
2Arsenic Trioxide (Trisenox)FDA Link
05/2016 - 06/2013
2Protein Isoforms (Isoforms)IBA
12/2015 - 10/2011
2Sorafenib (BAY 43-9006)FDA Link
02/2015 - 10/2013
2Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
10/2014 - 10/2011
2KP 1339IBA
10/2013 - 06/2010
2DNA (Deoxyribonucleic Acid)IBA
04/2012 - 08/2010
1Deoxyglucose (2 Deoxy D glucose)IBA
01/2022
1CaveolinsIBA
10/2021
1ClathrinIBA
10/2021
1InterleukinsIBA
02/2021
1Matrix Metalloproteinases (MMPs)IBA
02/2021
1Cadherins (E-Cadherin)IBA
02/2021
1MetalloidsIBA
01/2021
1Sulfhydryl Compounds (Thiols)IBA
01/2021
1Metformin (Glucophage)FDA LinkGeneric
01/2021
1ATP-Binding Cassette Transporters (ABC Transporters)IBA
01/2021
1CobaltIBA
12/2020
1Cinacalcet (Sensipar)FDA Link
12/2020
1Calcium-Sensing ReceptorsIBA
12/2020
1XanthonesIBA
09/2020
1hydroxide ionIBA
09/2020
1SuspensionsIBA
09/2020
1trans-sodium crocetinate (crocetin)IBA
01/2020
1LipidsIBA
01/2020
1Acetates (Acetic Acid Esters)FDA Link
12/2019
1ChloridesIBA
12/2019
1Deferoxamine (Desferal)FDA LinkGeneric
10/2019
1Chelating AgentsIBA
10/2019
1Cathepsin BIBA
01/2019
1Biotin (Vitamin H)FDA Link
01/2019
1AntacidsIBA
12/2018

Therapy/Procedure

24Therapeutics
12/2021 - 12/2007
9Drug Therapy (Chemotherapy)
10/2021 - 02/2008
2Transplantation
11/2018 - 08/2012
2Oral Administration
01/2017 - 01/2017